Female and male partner age and menotrophin requirements influence pregnancy rates with human menopausal gonadotrophin therapy in combination with intrauterine insemination.
This study analyses the influence of female and male patient age and human menopausal gonadotrophin (HMG) requirements on clinical pregnancy rates and live birth rates with ovulation stimulation using HMG in combination with intrauterine insemination (IUI). In this study, 363 consecutive HMG/IUI treatment cycles in 184 patients carried out at a university fertility centre were analysed in a retrospective fashion. The main outcomes measured were clinical pregnancy rates and live birth rates. Increased female partner age (> or = 35) and male partner age (> or = 40) were found to negatively influence pregnancy rates with HMG/ IUI therapy. In addition, this study demonstrated a critical threshold of HMG requirements beyond which pregnancy did not occur. No pregnancies occurred in treatment cycles requiring > 25 ampoules (1875 IU) of menotrophins to achieve follicular maturity, irrespective of patient age. In conclusion, female partner age, male partner age, and HMG requirements all significantly influence pregnancy rates with HMG/IUI therapy.
Brzechffa
P R
PR
Department of Obstetrics and Gynecology, University of California at Los Angeles, School of Medicine, CA 90095-1740, USA.
Buyalos
R P
RP
D000328:Adult; D000367:Age Factors; D000368:Aged; D005260:Female; D006801:Humans; D007317:Insemination, Artificial, Homologous; D008297:Male; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011247:Pregnancy; D012189:Retrospective Studies
D008596:Menotropins